For research use only. Not for therapeutic Use.
Pravastatin Sodium（Cat No.:I008842）is a cholesterol-lowering medication from the statin class, used primarily to treat hypercholesterolemia and prevent cardiovascular disease. By inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, Pravastatin effectively reduces low-density lipoprotein (LDL) cholesterol levels while raising high-density lipoprotein (HDL) levels. Its unique water-solubility limits entry into muscle cells, which may reduce certain side effects commonly seen with other statins. Pravastatin Sodium is widely prescribed for managing cardiovascular risk, contributing to improved heart health and decreased incidence of stroke and heart attack.
| Catalog Number | I008842 |
| CAS Number | 81131-70-6 |
| Synonyms | Pravastatin Sodium; Mevalotin; Elisor; Lipostat; Pravachol; Pravaselect; Apo-Pravastatin; Apotex Brand of Pravastatin Sodium; Aventis Brand of Pravastatin Sodium; Bristacol; Bristol-Myers Squibb Brand of Pravastatin Sodium; CS 514; CS-514; CS514; Eli |
| Molecular Formula | C23H35NaO7 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate |
| InChI | InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1 |
| InChIKey | VWBQYTRBTXKKOG-IYNICTALSA-M |
| SMILES | CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)O.[Na+] |
| Reference | </br>1:Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. Luo D, Kim JH, Park C, Oh E, Park JB, Cui JH, Cao QR, Lee BJ.Int J Pharm. 2017 May 15;523(1):343-356. doi: 10.1016/j.ijpharm.2017.03.030. Epub 2017 Mar 19. PMID: 28330645 </br>2:Formulation and Pharmacokinetic Evaluation of Microcapsules Containing Pravastatin Sodium Using Rats. Puttegowda VD, Karki R, Goli D, Jha SK, Mudagal MP.Scientifica (Cairo). 2016;2016:7623193. doi: 10.1155/2016/7623193. Epub 2016 Aug 9. PMID: 27595040 Free PMC Article</br>3:Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions. Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH.Drug Deliv. 2016 Nov;23(9):3266-3278. Epub 2016 Apr 19. PMID: 27094305 </br>4:A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use. Suzuki M, Kanamori M, Hashimoto T, Hashimoto Y, Funakoshi R, Sasaki T.J Pharm Health Care Sci. 2015 Dec 18;2:1. doi: 10.1186/s40780-015-0033-4. eCollection 2016. PMID: 26819746 Free PMC Article</br>5:[Preparation and performance of pravastatin sodium-loaded chitosan microspheres]. Feng J, Liu Z, Yan Y, Hu M, Lu L, You W.Nan Fang Yi Ke Da Xue Xue Bao. 2015 Jun;35(6):879-82. Chinese. PMID: 26111689 </br>6:Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH.Int J Pharm. 2015 Apr 10;483(1-2):77-88. doi: 10.1016/j.ijpharm.2015.02.012. Epub 2015 Feb 7. PMID: 25666025 </br>7:Pravastatin sodium. Al-Badr AA, Mostafa GA.Profiles Drug Subst Excip Relat Methodol. 2014;39:433-513. doi: 10.1016/B978-0-12-800173-8.00008-8. Review. PMID: 24794911 </br>8:[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. Ma YR, Zhou Y, Zhang GQ, Rao Z, Huang J, Wei YH, Wu XA.Yao Xue Xue Bao. 2014 Jan;49(1):72-7. Chinese. PMID: 24783509 </br>9:Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for buccal delivery and treatment of patients with atherosclerosis. Yedurkar P, Dhiman MK, Petkar K, Sawant K.Drug Dev Ind Pharm. 2013 May;39(5):670-80. doi: 10.3109/03639045.2012.687379. Epub 2012 May 26. PMID: 22630116 </br>10:Bilayered transmucosal drug delivery system of pravastatin sodium: statistical optimization, in vitro, ex vivo, in vivo and stability assessment. Maurya SK, Bali V, Pathak K.Drug Deliv. 2012 Jan;19(1):45-57. doi: 10.3109/10717544.2011.644348. Epub 2011 Dec 23. PMID: 22191789 |
